captopril / Generic mfg. - LARVOL DELTA

The Use of Virtual Reality and Music Therapy for Hypertensive Urgency (clinicaltrials.gov) - P=N/A | N=130 | Completed | Sponsor: Ankara City Hospital Bilkent

New trial • Cardiovascular • Hypertension • Mood Disorders • Psychiatry

Dosing trajectories of antihypertensive agents among preterm neonates: A retrospective, cross-sectional analysis. (PubMed, PLoS One) - "Propranolol is often initiated at a target dose and maintained with less titration, while both captopril and esmolol are titrated more often. Younger gestational age patients typically required higher doses of propranolol."

Journal • Retrospective data • Cardiovascular • Hypertension

The use and efficacy of angiotensin-converting enzyme inhibitors for treatment of hypertension in young children following paediatric cardiac surgery: a case control comparison. (PubMed, Cardiol Young) - "High and medium dose angiotensin-converting enzyme inhibitor therapy had a greater effect in decreasing mean arterial pressure when compared to low dose."

Journal • Cardiovascular • Hypertension • Pediatrics

Construction of cardiac organoids derived from human induced pluripotent stem cells for cardiac disease modeling and drug evaluation (PubMed, Nan Fang Yi Ke Da Xue Xue Bao) - "Cardiac organoids derived from human induced pluripotent stem cells have been successfully constructed and can be used for cardiac disease modeling and drug evaluation."

Journal • Cardiovascular • Fibrosis • Heart Failure • Immunology • Reperfusion Injury • CD31 • PECAM1 • VIM

Multisystem Complications and Therapeutic Trends in Scleroderma Renal Crisis: Insight from a Five-Year Retrospective Cohort Study (KIDNEY WEEK 2025) - "Renal: Acute renal failure in 12.0% ESRD in 2.8%, renal transplant in 0.7%, Hemodilaysis in 2.1%, Cardiovascular: NSTEMI in 2.8%, STEMI in 0.8%, Neurological: Stroke in 2.3%, Pulmonary: Edema in 2.4%, Pulmonary Hypertension in 16.8%, Pulmonary fibrosis in 7.3%, Treatment: Antihypertensives: ACEi (Captopril in 2.4%, enalapril in 1.2%, and ARBs: Losartan in 5.6%, valsartan in 2.4%). Immune suppressants: Hydroxychloroquine (HCQ) in 7.9%, methotrexate (MTX) in 3.7%, mycophenolate in 12.7%, rituximab in 4.1%, prednisone in 18.4%, methylprednisone in 18.3% of the cohort...Low utilization of ACEi and ARBs indicates potential therapeutic gaps. Further research to refine treatment strategies is essential to improve mortality and patient outcomes."

Retrospective data • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Hypertension • Immunology • Nephrology • Pulmonary Arterial Hypertension • Pulmonary Disease • Renal Disease • Respiratory Diseases • Scleroderma • Systemic Sclerosis

Stepwise Ligand-Exchange Strategy for the High-Yield Synthesis of Water-Soluble, Metal-Doped MAg24 Nanoclusters. (PubMed, J Am Chem Soc) - "This strategy is compatible with a wide variety of ligands─including 4-mercaptobenzoic acid, 6-mercaptohexanoic acid, captopril, and l-glutathione─and supports diverse metal dopants without loss of yield. Photoluminescence (PL) studies reveal dopant- and ligand-dependent PL quantum yields ranging from 0.2 to 12.2%, with excited-state dynamics indicating that nonradiative decay decreases exponentially with increasing PL peak energy in accordance with the energy-gap law. These findings offer design guidelines for creating highly emissive, water-soluble Ag-based NCs via the rational choice of metal dopants and protecting ligands."

Journal

Predicting Pharmacokinetics of Drugs in Patients with Heart Failure and Optimizing Their Dosing Strategies Using a Physiologically Based Pharmacokinetic Model. (PubMed, Pharmaceutics) - "Eight commonly used drugs (digoxin, furosemide, bumetanide, torasemide, captopril, valsartan, felodipine and midazolam) for treating HF and its comorbidities were selected. A PBPK model was successfully developed to predict the plasma concentration-time profiles of the eight tested drugs in both healthy subjects and HF patients. Furthermore, this model may also be applied to guide digoxin dose optimization for HF patients."

Journal • PK/PD data • Cardiovascular • Congestive Heart Failure • Heart Failure

Effect of Sacubitril/Valsartan, Ivabradine, and Captopril on Anxiety-like Behavior in Spontaneously Hypertensive Rats. (PubMed, Int J Mol Sci) - "Additionally, correlation analysis indicated that anxiety-like behavior in Wistar rats or SHR, either with or without cardiovascular therapy, was independent of SBP, HR, LVW, or LVHP. The level of anxiety-like behavior can, therefore, be considered part of the inherent neurobehavioral traits unrelated to fundamental hemodynamic or structural cardiovascular parameters."

Journal • Preclinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Mood Disorders • Psychiatry

Biochemical, histopathological, and immunohistochemical study on the ameliorative effect of crocin against lipopolysaccharide‑induced hippocampal toxicity in male albino rats. (PubMed, BMC Pharmacol Toxicol) - "The present study suggests that crocin acts as a promising therapeutic agent for alleviating memory impairments and neuroinflammation induced by LPS."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Oncology • CAT • CHAT • IL1B • TNFA

Rifampicin-induced challenges in managing endocrine hypertension and primary aldosteronism: a case report and literature review. (PubMed, Front Pharmacol) - "He was suspected of having Primary Aldosteronism (PA) and subclinical Cushing's Syndrome (SCS) based on elevated aldosterone-to-renin ratio (ARR), captopril challenge test results (CCT), and low-dose dexamethasone suppression test (LDDST) results...Despite being on six antihypertensive medications, including spironolactone, his blood pressure remained uncontrollable...Specifically, the use of rifampicin, a potent CYP450 inducer, resulted in false-positive diagnostic test results and diminished efficacy of antihypertensive medications, thereby contributing to RHTN. When encountering uncontrolled hypertension, particularly when standard treatments fail, awareness of DDIs is crucial for accurate diagnosis and effective management."

Journal • Cardiovascular • Cushing’s Disease • Endocrine Disorders • Hypertension

Idiophatic Pulmonary Hypertension in Children Mongolia: A Case Report (APSR 2025) - "The treatment was initiated with furosemide (1 mg/kg/day) and captopril (1 mg/kg/d) in 1 year and sildenafil (1 mg/kg/d) was combined in last 5 months. 2 case was diagnosed during pathoanatomy section, 5 case diagnosed alive and 3 of them died althouth treated with combination therapy. 2 of them are still alive."

Case report • Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Treatment of Hypertensive Crisis in Primary Care Health Facilities in Peru, 2019-2024. (PubMed, High Blood Press Cardiovasc Prev) - "Short-acting antihypertensives and other agents remain common in Peruvian primary care hypertensive crises. Targeted strategies are needed to align practice with evidence-based recommendations."

Journal • Cardiovascular • Hypertension

Effects of antihypertensives on the degradation behavior of AZ31 alloy in in-vitro environment. (PubMed, Sci Rep) - "Effects of seven antihypertensives of Losartan Kalicum(LK), Atenolol(ATEN), Nifedipine(NF), Hydrochlorothiazide(HCTZ), Valsartan(VLA), Furosemide(FUR) and Captopril(CAP) have been investigated on the degradation behavior of AZ31 alloy in simulated body fluid (Hank's solution). The surface analysis reveals that the addition of LK, NF and HCTZ can reduce degradation rate by promoting the growth of hydroxyapatite, increasing the protection effect of corrosion film formed. The present results may enhance the corrosion resistance of Mg-based orthopedic implants."

Journal • Preclinical • Orthopedics

Act Before It's Too Late: Avoid Mixed Connective Tissue Disease's Rare Renal Fate (KIDNEY WEEK 2025) - "He started prednisone, hydroxychloroquine (HCQ) and dual vasodilators for MCTD with PAH...Captopril was initiated, but he ultimately required hemodialysis...Discussion This case highlights an insidious presentation of SRC in MCTD, which could represent its own distinct syndrome separate from SRC. We hypothesize that in the context of corticosteroids, the pathogenesis was hastened by radiocontrast exposure, aggressive diuresis, and removal of endothelin-receptor antagonism that may have been masking early signs of SRC."

Anemia • Autoimmune Hemolytic Anemia • Cardiomyopathy • Cardiovascular • Hematological Disorders • Hypertension • Immunology • Nephrology • Pulmonary Arterial Hypertension • Pulmonary Disease • Renal Disease • Respiratory Diseases • Rheumatology • Scleroderma • Systemic Sclerosis

From Fibrosis to Failure: A Severe Case of Scleroderma Renal Crisis (KIDNEY WEEK 2025) - "She received ACE inhibitors, plasmapheresis for 5 days, and captopril 50 mg TID, with improved renal function. Complement inhibition with eculizumab shows variable benefit; further studies are warranted. Light microscopy showed global glomerulosclerosis, ischemic hypoperfusion, onion-skinning of arterioles Electron microscopy shows endothelial swelling, thin BM and no immune complex deposition."

Clinical • Acute Kidney Injury • Anemia • Cardiovascular • Congestive Heart Failure • Fibrosis • Glomerulonephritis • Heart Failure • Hypertension • Immunology • Nephrology • Renal Disease • Rheumatology • Scleroderma • Systemic Sclerosis • Thrombocytopenia

Plasmapheresis for Treatment of Renal Scleroderma Crisis (KIDNEY WEEK 2025) - "She was treated with captopril 50 mg TID, amlodipine 10 mg daily, and plasmapheresis...Though data are limited, case series suggest combining plasmapheresis with ACE inhibition may improve renal recovery and outcomes. In this case, the dual approach led to rapid improvement and preserved renal function, supporting its potential role in SRC."

Acute Kidney Injury • Anemia • Cardiovascular • Hypertension • Immunology • Nephrology • Renal Disease • Rheumatology • Scleroderma • Systemic Sclerosis • Thrombocytopenia

Stabilizing Nitric Oxide: MnFe2O4@Cap-SNO nanoparticles and Chitosan Hydrogels for Controlled Therapeutic Delivery. (PubMed, Nitric Oxide) - "MnFe2O4@Cap-SNO, incorporating captopril (Cap) as an NO donor, demonstrated prolonged NO release for up to 16 hours upon light exposure, following zero-order kinetics, ensuring sustained delivery...These findings suggest MnFe2O4@Cap-SNO as an effective NO-stabilizing carrier for biomedical applications, particularly intargeted drug delivery. Future studies will focus on in vitro and in vivo validation to assess therapeutic efficacy."

Journal

Effectiveness of Short-Acting Oral Antihypertensives in Asymptomatic Markedly Elevated Blood Pressure: An Inverse Probability Treatment Weighted Study. (PubMed, J Clin Med Res) - "Although urgent BP reduction is not routinely recommended in the ED, oral captopril appears to be a reasonable first-line option when clinically necessary, while hydralazine may be a suitable alternative. Combination of these two drugs should be used with caution due to the risk of excessive MAP reduction."

Journal • Cardiovascular • Hypertension

Deciphering Mechanosensitive Transcriptional Components Within the Renin Cell Baroreceptor (KIDNEY WEEK 2025) - "Mice were then tested under hypotensive stress induced by captopril and a low-sodium diet, as well as AoCo-induced pressure changes...Klf2 cKO mice exhibited increased susceptibility to hypotensive conditions and displayed impaired renin responses to changes in perfusion pressure. Conclusion Klf2 is a pressure-sensitive transcription factor for renin expression and plays a key role in the control of the renin cell baroreceptor."

Cardiovascular • Hypertension • EGR1

In Times of Crisis: Delayed Diagnosis of Scleroderma Renal Crisis in Limited Systemic Sclerosis (KIDNEY WEEK 2025) - "Patient was diagnosed with SRC and started on Captopril, eventually requiring long-term hemodialysis...Over 50% of SRC patients require renal replacement therapy, as seen in this case. Thus, here we highlight the risk of delayed SRC diagnosis and reinforce the need for early recognition to prevent irreversible outcomes such as the need for chronic hemodialysis."

Acute Kidney Injury • Anemia • Cardiovascular • Endocrine Disorders • Fatigue • Hematological Disorders • Immunology • Musculoskeletal Diseases • Musculoskeletal Pain • Nephrology • Orthopedics • Pulmonary Disease • Renal Disease • Respiratory Diseases • Rheumatology • Scleroderma • Systemic Sclerosis

When Chest Pain Defies Coronary Assumptions, Remember Scleroderma (KIDNEY WEEK 2025) - "He was started on mycophenolate and captopril for SRC, and creatinine stabilized at 2.6 mg/dL...Clinicians should maintain a high level of suspicion for this rare disease in patients with skin and musculoskeletal changes. Anti-RNA polymerase III antibodies should be checked as soon as possible in patients with suspected renal involvement."

Acute Kidney Injury • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Immunology • Musculoskeletal Diseases • Nephrology • Pain • Rare Diseases • Renal Disease • Rheumatology • Scleroderma • Systemic Sclerosis

Two Cases of Autoimmune and Genetic Triggers of Thrombotic Microangiopathy Involving Complement Mutations in Systemic Sclerosis (KIDNEY WEEK 2025) - "She was treated with captopril but remained dialysis-dependent. Eculizumab was not administered due to family concerns regarding infection risk...Our report supports the “two-hit” hypothesis in TMA and highlights the importance of adding genetics to the autoimmune work-up in patients with SSc. Complement inhibition may be a valuable therapeutic option in selected cases."

Clinical • Acute Kidney Injury • Atypical Hemolytic Uremic Syndrome • CNS Disorders • Complement-mediated Rare Disorders • Immunology • Infectious Disease • Musculoskeletal Pain • Nephrology • Pulmonary Disease • Renal Disease • Scleroderma • Systemic Sclerosis • HP

Congenital Nephrotic Syndrome in a Hispanic Neonate Due to a Rare NPHS1 c.3024A>G Variant (KIDNEY WEEK 2025) - "The sole published case (DOI: 10.3892/br.2021.1487) proposed that this synonymous change disrupts FOX1L1/FOXC1 binding in exon 22, dysregulating nephrin expression...The patient eventually developed edema at approximately DOL 21 and therapy comprised IV albumin infusions along with furosemide, metolazone, indomethacin, captopril, and enoxaparin...First, we describe a “silent” NPHS1 variant that is likely pathogenic; early genetic testing is therefore essential for accurate diagnosis and counseling. Second, family-centered and multidisciplinary approach can achieve patient stability with medical management alone, especially in rare genetic diseases."

Genetic Disorders • Glomerulonephritis • Nephrology • Renal Disease • FOXC1 • NPHS1

Scleroderma Renal Crisis (KIDNEY WEEK 2025) - "Other relevant history includes prior use of Ibuprofen 800 mg, 2-3 times a week for 1.5 months and workout supplemental protein...He received captopril within 24 hours of presentation given his history, which was titrated up to 62.5 mg, Q8 hourly. Carvedilol 25 BID and amlodipine 10 mg daily were also added for his BP...Newer agents like eculizamab and ravulizumab (complement C5 inhibitors) have shown some efficacy in SRC in small studies. SRC continues to be a grave complication of scleroderma. Prompt diagnosis and early BP control can prevent its progression but prognosis remains poor."

Acute Kidney Injury • Cardiovascular • Complement-mediated Rare Disorders • Eosinophilia • Hepatitis B • Hepatitis C • Human Immunodeficiency Virus • Hypertension • Immunology • Infectious Disease • Renal Disease • Rheumatology • Scleroderma • Systemic Sclerosis

ACE2 Amplification, Unlike ACE Inhibition, Does Not Suppress Plasma Aldosterone: Implications for Hyperkalemia (KIDNEY WEEK 2025) - "Its effect on plasma aldosterone was compared to the administration of the ACE inhibitor, captopril (60 mg/kg/d in drinking water), also for one week...Conclusion Downregulation of RAS using a shorter form of soluble ACE2, unlike blocking the formation of Ang II using an ACE inhibitor, does not reduce plasma aldosterone. This attribute of ACE2618ABD should represent a potentially important advance by eliminating the risk of hyperkalemia in patients with CKD and heart failure in need of RAS downregulation."

Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure